tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Bicara Therapeutics initiated with an Overweight at Piper Sandler
PremiumThe FlyBicara Therapeutics initiated with an Overweight at Piper Sandler
2M ago
Bicara Therapeutics initiated with an Overweight at Piper Sandler
Premium
The Fly
Bicara Therapeutics initiated with an Overweight at Piper Sandler
2M ago
Bicara Therapeutics Reports Q2 2025 Results and Progress
Premium
Company Announcements
Bicara Therapeutics Reports Q2 2025 Results and Progress
2M ago
Bicara Therapeutics Expands Boston Headquarters with New Lease
PremiumCompany AnnouncementsBicara Therapeutics Expands Boston Headquarters with New Lease
4M ago
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
Premium
Ratings
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
4M ago
Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating
Premium
Ratings
Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating
4M ago
Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today?
PremiumMarket NewsWhy Is Bicara Therapeutics Stock (BCAX) Down 30% Today?
4M ago
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics
Premium
Ratings
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics
4M ago
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating
Premium
Ratings
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100